Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...

July 2, 2004 — Continuous subcutaneous insulin infusion (CSII) improved glycemic control in children and adolescents with type 1 diabetes better than did multiple daily injection (MDI) with glargine, ...

Please provide your email address to receive an email when new articles are posted on . 52-week study included 85 adults with Parkinson’s and at least 3 hours/day of “off” time. At week 12, CSAI led ...

GIP infusion as add-on to placebo or semaglutide did not improve glycaemic control in individuals with type 2 diabetes at the prespecified target of 1·50 mmol/L. Due to dropouts, we cannot draw firm ...

A 24-hour continuous subcutaneous infusion of foslevodopa/foscarbidopa improved Parkinson's disease (PD) motor symptoms during all waking hours for patients with ...

The FDA approved a subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson's disease, AbbVie announced Thursday. Foscarbidopa and foslevodopa are ...

Credit: Thinkstock. The randomized, double-blind, double-dummy, active-controlled study compared ABBV-951 via continuous SC infusion to oral levodopa/carbidopa. Positive results were announced from a ...

The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...

AbbVie Inc. said Thursday the Food and Drug Administration has approved its vyalev as the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor ...

The number of patients with Parkinson's disease (PD) who initiated device-aided therapies (DAT) increased by 41.8% between ...